#ACC21: Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

When Re­gen­eron scored an ear­ly ap­proval for lipid low­er­ing an­ti­body Evkeeza back in Feb­ru­ary, the drug­mak­er cracked open a new path­way to low­er ab­nor­mal­ly high cho­les­terol lev­els. Now, Re­gen­eron is chas­ing high triglyc­erides as well with some promis­ing mid-stage da­ta — but will ge­net­ic re­stric­tions lim­it the drug’s use?

Re­gen­eron’s Evkeeza (evinacum­ab) cut me­di­an triglyc­eride lev­els by more than 800 mg/dL (57%) in pa­tients with a rare dis­or­der caus­ing ab­nor­mal­ly high triglyc­eride lev­els com­pared with an over­all in­crease of 50 mg/dL (1.8%) in par­tic­i­pants on place­bo, ac­cord­ing to Phase II da­ta pre­sent­ed Sun­day at the vir­tu­al Amer­i­can Col­lege of Car­di­ol­o­gy meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.